The complete phase I results of mRNA-1273 vaccine against SARS-CoV2
Moderna released the complete phase I results of its mRNA-1273 vaccine against SARS-CoV2. An immune response was observed in all participants (45 participants, 18 to 55 years of age), confirming the first interim analyzes published in May.
These data are positive and allow the launch of phase III at the end of July, in line with the company’s calendar.
Data is very encouraging but the development is still at an early stage. Phase III will 1/ determine the extent and durability of the immune response, 2/ confirm these initial results on a larger number of participants but also in an older population.